GS 2992
Latest Information Update: 22 May 2001
At a glance
- Originator Gilead Sciences
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 22 May 2001 Profile reviewed but no significant changes made
- 02 Sep 1998 No-Development-Reported for HIV-1 infections in USA (PO)
- 15 May 1995 New profile